|
||||||||||||||||||||||
|
|
Alternate Title Randomized, Placebo-Controlled Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer
Trial Description Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by reducing the production of estrogen. Trial to study the effectiveness of tamoxifen in preventing invasive breast cancer, in reducing breast cancer deaths in women at increased risk, and in reducing broken bones and deaths caused by heart disease in these women.
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Participants will be randomized to one of two groups: those taking tamoxifen by mouth once a day for 5 years; or those taking a placebo by mouth once a day for 5 years. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations National Surgical Adjuvant Breast and Bowel Project
|
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |